Statement: Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea.
Primary_evidence: Adverse Events 1:   Total: 20/167 (11.98%)   Cardiac failure acute 0/167 (0.00%)   Diarrhoea 5/167 (2.99%)   Colitis 2/167 (1.20%)   Enterocolitis 1/167 (0.60%)   Enterocolitis haemorrhagic 1/167 (0.60%)   Stomatitis 1/167 (0.60%)   Impaired healing 1/167 (0.60%)   Sudden death 1/167 (0.60%)   Postoperative wound infection 2/167 (1.20%)   Erysipelas 2/167 (1.20%)   Bacterial diarrhoea 1/167 (0.60%) Adverse Events 2:   Total: 4/167 (2.40%)   Cardiac failure acute 1/167 (0.60%)   Diarrhoea 0/167 (0.00%)   Colitis 0/167 (0.00%)   Enterocolitis 0/167 (0.00%)   Enterocolitis haemorrhagic 0/167 (0.00%)   Stomatitis 0/167 (0.00%)   Impaired healing 0/167 (0.00%)   Sudden death 0/167 (0.00%)   Postoperative wound infection 1/167 (0.60%)   Erysipelas 0/167 (0.00%)   Bacterial diarrhoea 0/167 (0.00%)